美贝维林与标签对肠易激综合征或非特指功能性腹痛青少年的影响:一项2×2随机安慰剂对照试验
该2×2随机安慰剂对照试验在13家医院纳入269例12-17岁肠易激综合征或非特指功能性腹痛青少年,评估美贝维林(200 mg每日两次,8周)疗效及标签效应。美贝维林组与安慰剂组治疗成功率相似(23.4% vs 22.0%;OR 1.08;95%CI 0.59-1.99;P=0.81),但美贝维林标签组成功率高于盲法试验标签组(31.6% vs 14.1%;OR 2.84;95%CI 1.52-5.34;P=0.001)。结论认为美贝维林无效,而正面药物标签显著改善治疗结局。
要点
- 美贝维林组与安慰剂组8周治疗成功率无显著差异(23.4% vs 22.0%)。
- 美贝维林标签组治疗成功率显著高于盲法试验标签组(31.6% vs 14.1%)。
- 不良反应轻微且不常见。
核心结论
- 美贝维林对儿童肠易激综合征和非特指功能性腹痛无效。
- 与盲法试验标签相比,正面药物标签显著改善治疗结局。
研究设计与样本
- 2×2随机安慰剂对照试验,在13家医院开展。
- 纳入269例12-17岁肠易激综合征或非特指功能性腹痛患者。
- 美贝维林200 mg每日两次或安慰剂治疗8周,按1:1:1:1随机分为四组:美贝维林-盲法试验标签、美贝维林-美贝维林标签、安慰剂-盲法试验标签、安慰剂-美贝维林标签。
- 随机化对医生设盲,但药物标签除外。
主要发现
- 美贝维林组(第1和第2组)治疗成功31例(23.4%),安慰剂组(第3和第4组)30例(22.0%);OR 1.08;95%CI 0.59-1.99;P=0.81。
- 美贝维林标签组(第2和第4组)治疗成功42例(31.6%),盲法试验标签组(第1和第3组)19例(14.1%);OR 2.84;95%CI 1.52-5.34;P=0.001。
- 美贝维林组充分缓解55例(41.0%),安慰剂组61例(45.5%);OR 0.83;95%CI 0.51-1.35;P=0.46。
- 美贝维林标签组充分缓解67例(50.4%),盲法试验标签组49例(36.3%);OR 1.78;95%CI 1.1-2.9;P=0.02。
- 不良反应轻微且不常见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified lack effective pharmacologic interventions. The efficacy of mebeverine, an antispasmodic agent, and the effect of labeling within a pediatric cohort were evaluated. METHODS: This randomized trial was conducted across 13 hospitals. Participants (12-17 years) with irritable bowel syndrome or functional abdominal pain-not otherwise specified received mebeverine (200 mg twice daily) or placebo for 8 weeks. Treatment was labeled as "mebeverine or placebo" (blinded trial label) or "mebeverine" (mebeverine label), creating the following 4 groups: (1) mebeverine-blinded trial label, (2) mebeverine-mebeverine label, (3) placebo-blinded trial label, and (4) placebo-mebeverine label. Randomization (1:1:1:1) was masked to physicians, except for drug labeling. Primary end point was treatment success (>50% reduction of abdominal pain intensity and frequency) after 8 weeks. The key secondary end point was adequate relief of symptoms. RESULTS: Of the 269 randomized patients, treatment success was similar between those receiving mebeverine (groups 1 and 2) (n = 31 [23.4%]) and placebo (groups 3 and 4) (n = 30 [22.0%]; odds ratio [OR], 1.08; 95% CI, 0.59-1.99; P = .81). Treatment success was higher in groups with the mebeverine label (groups 2 and 4) (n = 42 [31.6%]) compared with the blinded trial label (groups 1 and 3) (n = 19 [14.1%]; OR, 2.84; 95% CI, 1.52-5.34; P = .001). Adequate relief rates were similar between mebeverine (n = 55 [41.0%]) and placebo groups (n = 61 [45.5%]; OR, 0.83; 95% CI, 0.51-1.35; P = .46), but higher in mebeverine-labeled groups (n = 67 [50.4%]) compared with blinded trial-labeled groups (n = 49 [36.3%]; OR, 1.78; 95% CI, 1.1-2.9; P = .02). Adverse events were mild and infrequent. CONCLUSIONS: Mebeverine was ineffective in treatment of pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified. However, a positive drug label significantly enhanced treatment outcomes compared with a blinded trial label. (International Clinical Trials Registry Platform, Number: NL-OMON55563.).
引用
- Rexwinkel R, Vermeijden NK, Zeevenhooven J, et al. Mebeverine and the Influence of Labeling in Adolescents With Irritable Bowel Syndrome or Functional Abdominal Pain Not Otherwise Specified: A 2 × 2 Randomized, Placebo-Controlled Trial. Gastroenterology. 2025. PMID: 40074185. doi:10.1053/j.gastro.2025.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。